NCT04853199View on ClinicalTrials.gov

Quercetin In The Treatment Of SARS-COV 2

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 30, 2021

Study Completion Date

August 30, 2021

Conditions
SARS (Severe Acute Respiratory Syndrome)
Interventions
DRUG

Quercetin

Each patient should receive one tablet twice a day 30 minutes before the meal

DRUG

Placebo

Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.

Trial Locations (2)

4054

HU Sahloul, sousse, Tunisia, Sousse

Unknown

Riadh Boukef, Sahloul

All Listed Sponsors
lead

Hôpital Universitaire Sahloul

OTHER